What is a concise summary of the management plan for patients with type 2 diabetes?

Management of Type 2 Diabetes: A Structured Approach

For patients with type 2 diabetes, prioritize a complications-centric approach that addresses cardiovascular and kidney disease risk first, followed by glycemic and weight management goals, using early combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors as preferred first-line agents over insulin. 1, 2

Initial Assessment and Treatment Framework

Medication Selection Based on Comorbidities

If the patient has heart failure (reduced or preserved ejection fraction):

• Start an SGLT2 inhibitor immediately for glycemic management and prevention of heart failure hospitalizations 1

If the patient has chronic kidney disease (eGFR 20-60 mL/min/1.73 m² or albuminuria):

• Use an SGLT2 inhibitor to minimize CKD progression, reduce cardiovascular events, and prevent heart failure hospitalizations 1
• Note: Glycemic benefits diminish at eGFR <45 mL/min/1.73 m² 1

If the patient has advanced CKD (eGFR <30 mL/min/1.73 m²):

• Prefer a GLP-1 receptor agonist for glycemic management due to lower hypoglycemia risk and cardiovascular event reduction 1

If the patient has no cardiovascular or kidney disease:

• Select agents that address both individualized glycemic and weight goals 1
• Consider early combination therapy, especially if HbA1c >8.5% at diagnosis or in younger patients 1

Pharmacologic Treatment Hierarchy

First-Line Therapy

GLP-1 receptor agonists (including dual GIP/GLP-1 agonists) are preferred over insulin for most patients due to superior weight outcomes, lower hypoglycemia risk, and cardiovascular benefits 1

When to Use Insulin Immediately

Initiate insulin regardless of background therapy if any of the following are present 1:

• Evidence of ongoing catabolism (unexpected weight loss)
• Symptoms of hyperglycemia
• HbA1c >10% (>86 mmol/mol)
• Blood glucose ≥300 mg/dL (≥16.7 mmol/L)

If insulin is required, combine it with a GLP-1 receptor agonist for greater glycemic effectiveness, beneficial weight effects, and reduced hypoglycemia risk 1

Treatment Intensification Strategy

Combination Therapy Approach

• Add medications rather than substitute them to incorporate complementary mechanisms of action 1
• Consider fixed-dose combinations to reduce prescription burden and improve adherence 1
• Discontinue sulfonylureas when starting insulin to avoid hypoglycemia 1

Medication Review Schedule

Reassess every 3-6 months 1:

• Medication-taking behavior and adherence
• Efficacy (HbA1c, weight)
• Safety and adverse effects
• Need for dose adjustment of hypoglycemia-causing medications when adding new glucose-lowering agents 1

De-intensification Criteria

Reduce or stop medications when 1:

• HbA1c falls below 6.5% (48 mmol/mol) or substantially below individualized target
• Increased hypoglycemia risk develops
• Minimal benefits or harm outweighs benefit
• Clinical circumstances change (development of comorbidities, frailty in older adults)

Weight Management Integration

For patients not achieving weight goals, add 1:

• Intensified lifestyle modifications
• Structured weight management programs
• Pharmacologic weight management agents
• Consider metabolic surgery when appropriate

The glucose-lowering treatment plan must support weight management goals, as weight reduction is a key pillar in diabetes management 1, 2

Lifestyle Interventions as Foundation

All six pillars of lifestyle medicine should be addressed 3:

• Plant-predominant nutrition
• Regular aerobic and muscle-strengthening physical activity
• Restorative sleep (screen for sleep disorders)
• Stress reduction
• Social connectedness and peer/familial support
• Avoidance of tobacco, excessive alcohol, and recreational drugs

Common Pitfalls to Avoid

Therapeutic inertia: Re-evaluate at every visit and intensify therapy promptly when targets are not met 1

Delaying effective therapy: Early combination therapy shortens time to goal attainment, particularly in younger patients or those with high baseline HbA1c 1

Ignoring cardiorenal protection: Prioritize SGLT2 inhibitors and GLP-1 receptor agonists in at-risk patients even if glycemic control is adequate 1, 2

Continuing ineffective medications: Stop agents that provide minimal benefit or cause harm 1

Overlooking medication costs and access: Consider health equity factors in treatment selection as these affect adherence and outcomes 2